REGENXBIO Inc. (RGNX) stock
RGNXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 4/30
$7.24−0.08 (-1.09%)
Close on Nov 17, 2026Market cap $477.94MP/E –Yield –
Regenxbio EV/EBITDA
EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.
Regenxbio's EV/EBITDA was 3.2× on Jan 31, 2023, against 14.7× a year earlier. Over the last 2 years it ranged from 1.0× to 39.5×, with a median of 14.1×.
EV/EBITDA at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2023 | Jan 31, 2023 | 3.2× | +0.2 |
| 2022 | Dec 30, 2022 | 3.0× | −11.6 |
| 2019 | Apr 30, 2019 | 14.7× | +0.5 |
| 2018 | Dec 31, 2018 | 14.1× | – |
See a number that looks wrong?